Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX) has launched a new high-throughput, robotics-compatible reagent kit for automating single-cell discovery studies. The solution includes the BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform. This collaboration aims to standardize manual processes and accelerate genetic sequencing material generation.

The automation addresses challenges in DNA library preparation, such as variability, compromised data quality, throughput, high costs, and long turnaround times. It offers increased consistency, efficiency, and reproducibility in experiments, particularly beneficial for oncology and immunology research.

The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR platform are now commercially available worldwide.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has announced that it will report its fiscal 2024 fourth quarter and full year financial results on Thursday, Nov. 7, 2024. A news release will be issued at approximately 6:30 a.m. ET, with related presentation materials available on the company's investor relations website.

BD management will host an audio webcast at 8 a.m. ET on the same day to discuss the financial results and provide updates on operations and strategy. The company has also announced dates for its fiscal 2025 quarterly earnings webcasts, which are scheduled for February 6, May 1, July 31, and November 6, 2025.

BD (NYSE: BDX) has reached an agreement to resolve the majority of its existing hernia litigation, including cases in Rhode Island and Ohio. The settlement amount, which is confidential, falls within the company's current product litigation reserve and will be paid over multiple years. This agreement is structured to eliminate uncertainty for all stakeholders related to the settled cases.

Key points:

• No admission of liability or wrongdoing by BD
• Settlement will not impact BD's cash flow goals or capital allocation strategy
• No incremental charge to BD's consolidated income statement
• BD will continue to defend itself in unresolved cases

BD emphasizes its commitment to patient safety and product quality, acknowledging that all implantable medical devices carry inherent risks and benefits.

BD (NYSE: BDX) announced new data highlighting the effectiveness of its artificial intelligence technology in detecting controlled substance diversion in hospital operating rooms. A study conducted at an Ochsner Health medical center, published in the American Journal of Health-System Pharmacy, showed that BD HealthSight™ Diversion Management software can identify blind spots in medication movement undetected by manual processes.

Key findings include:

• 55% increase in charting discrepancies detected
• 14% increase in incidents resolved by operating room analysts
• 10% decrease in cases requiring additional documentation
• Reduction in auditor review time from 3 business days to 50 minutes

The study emphasizes the importance of advanced analytics in combating drug diversion, a persistent issue in healthcare settings.

BD (NYSE: BDX) has announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and expanded capacity for its BD Neopak™ Glass Prefillable Syringe platform. This expansion aims to serve the growing biologics market, with the platform already approved for over 24 indications. The XtraFlow™ syringe features an 8mm needle and thinner wall cannula, optimizing delivery of high-viscosity drugs by reducing injection force and time.

BD has also integrated a high-volume manufacturing line at its Le Pont-de-Claix, France site, increasing production capacity sevenfold. This expansion enhances BD's ability to meet the evolving needs of pharmaceutical partners and patients, particularly in the growing biologics segment for novel drug formulations in areas such as metabolic disorders and oncology.

Edwards Lifesciences (NYSE: EW) has completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in cash. The company plans to use the proceeds for strategic initiatives, including acquisitions and share repurchases. CEO Bernard Zovighian emphasized the company's sharpened focus on structural heart innovation, highlighting growth opportunities in TAVR, TMTT, and surgical leadership.

Edwards also announced an additional $1.5 billion authorization for share repurchase. The company has already initiated a $500 million Accelerated Share Repurchase agreement and previously repurchased $500 million of common stock. After this $1 billion share repurchase, Edwards will have $1.4 billion remaining for future repurchases.

BD (Becton, Dickinson and Company) has completed the acquisition of Edwards Lifesciences' Critical Care product group, now renamed as BD Advanced Patient Monitoring. This acquisition expands BD's portfolio of smart connected care solutions with leading monitoring technologies and AI-enabled clinical decision tools. The combination of BD's new advanced monitoring and existing infusion platforms enables future innovation opportunities for closed-loop monitoring and treatment.

Key points:

• BD Advanced Patient Monitoring will be based in Irvine, California
• It becomes part of BD's Medical segment
• Katie Szyman will continue as worldwide president
• The acquisition is expected to have an immaterial impact on BD's fiscal year 2024 guidance

BD (Becton, Dickinson and Company) celebrated the 75th anniversary of its manufacturing operations in Columbus, Nebraska. The event highlighted the importance of domestic production for critical medical devices. The Columbus facility, which started in 1949 with 15 employees, now employs 2,100 associates across three locations and one million square feet.

Key points:

• BD Columbus is one of only two remaining large-scale syringe manufacturing sites in the U.S.
• The facility has boosted domestic syringe production by 50% in the first nine months of 2024
• BD has invested $200 million in capital over the last four years in Columbus
• The company recognized long-tenured associates, including two with over 47 years of service

The celebration emphasized BD's commitment to U.S. manufacturing and its role in strengthening the medical supply chain's resilience.

BD (NYSE: BDX) has appointed Michael Feld as the new executive vice president and president of its Life Sciences segment, effective Aug. 20, 2024. Feld, who will join the Executive Leadership Team, succeeds Dave Hickey, who retired last month after a decade with the company. Feld comes from Veralto, a Danaher spin-off, where he was president of Hach. His experience includes senior roles at Danaher, focusing on strategic planning, quality, and cultural progression.

As president of BD Life Sciences, Feld will oversee Biosciences, Diagnostics Solutions, and Specimen Management. The segment aims to deliver innovative advancements from discovery to diagnosis, focusing on smart, connected workflows and diagnostics in new care settings to improve chronic condition management.